Key facts
- Baylor Genetics’s last known valuation is $326.0M (Mar 2025).
- It has raised $102.0M; the latest was Later Stage VC ($102.0M) in Mar 2025.
- Notable investors include Baylor College Of Medicine, Decheng Capital, H.U. Group Holdings.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Baylor Genetics
- ·The full record, as it builds
Funding rounds
No funding rounds for Baylor Genetics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Baylor Genetics
Provider of genetic testing and precision medicine services intended to provide deep patient data sets that lead to accurate interpretations. The company offers whole-exome sequencing, prenatal diagnostics, cytogenetics, molecular diagnostics, oncology, and interpretation services, enabling healthcare providers to make informed decisions.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2015
- Employees
- 540
- Website
- baylorgenetics.com/
- Ownership
- Privately Held (backing)
Baylor Genetics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Baylor Genetics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Baylor Genetics in its N-PORT filings yet. We sweep new filings monthly.